Viking Therapeutics, Inc(NASDAQ:VKTX) 
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR), ...
Website: http://www.vikingtherapeutics.com
Founded: 2012
Full Time Employees: 17
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 23.41
H 23.66
L 21.53
C 22.62
V 6,565,524
10EMA 22.62
20EMA 22.62
60EMA 22.62
120EMA 22.62
250EMA 22.62